Guidelines update addresses dose reduction and discontinuation of DMARDs in rheumatoid arthritis, suggesting new strategies.
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with a significant addition and expansion to an existing recommendation addressing the dose reduction/tapering and discontinuation of disease-modifying antirheumatic drugs (DMARDs). New recommendations now encompass conventional synthetic, targeted synthetic, and biologic DMARDs.
No takes yet. Share an insight, caveat, or question.
Nikolic et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: